Innovent Biologics, Inc. (HKG:1801)
102.40
+1.20 (1.19%)
Aug 21, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change
1,843
Growth
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
178.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Jun 30, 2025 | 6,190 | - | - |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| BeOne Medicines AG | 12,000 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| Akeso | 3,761 |
| RemeGen | 3,048 |
Innovent Biologics News
- 11 days ago - Innovent, Daiichi Sankyo Ink China Deal For VANFLYTA Commercialization - Nasdaq
- 11 days ago - Innovent Biologics Secures China Commercialization Rights For Vanflyta In Deal With Daiichi Sankyo - Nasdaq
- 11 days ago - Daiichi Sankyo, Innovent enter exclusive agreement for Vanflyta in China - TheFly
- 11 days ago - Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China - PRNewsWire
- 5 weeks ago - Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
- 5 weeks ago - Spero Therapeutics, Innovent Biologics enter license agreement for SP001 - TheFly
- 7 weeks ago - Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement - TheFly
- 7 weeks ago - China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug - Reuters